[PHOENIX, AZ and NEW DELHI, INDIA, May 18, 2016]– Paradigm, a molecular information & Next Generation Sequencing (NGS) corporation specializing in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with CORE Diagnostics to facilitate patient access to its cancer profiling service, PCDx, in India. Given this region’s continued investment in healthcare, Paradigm is poised to provide a growing community of oncologists and their patients the most relevant and actionable cancer care available.
“Expanding our testing services outside the US market is a key strategic initiative for Paradigm,” said David Mallery, President, Paradigm. “The relationship with CORE Diagnostics provides us with considerable external resources to rapidly expand testing and realize this goal while allowing better patient and physician access to PCDx abroad.”
PCDx is a comprehensive clinical-grade NGS-based test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumors DNA, RNA & Protein. The test interrogates the most relevant genomic targets at over 5,000x average depth of coverage with 72 therapeutic associations. Results are typically delivered in 4-5 business days.
Gurgaon-based CORE Diagnostics, offers a comprehensive menu of specialized, advanced diagnostic testing in India in the areas of cardiology, oncology, reproductive disorders, endocrinology and infectious diseases.
“With a focus on esoteric testing, an extensive experience in the region, and a dedicated diagnostics sales team of over 40, CORE is an ideal partner to Paradigm as it seeks to expand the reach of its PCDx tumor profiling service,” said Zoya Brar, Founder & Managing Director of CORE. “Paradigm’s offering would be a great addition to our portfolio. We are looking forward to this relationship with Paradigm and believe it will have a significant impact on improving the treatment of cancer patients in India.”
Core Diagnostics India is working with physicians from prominent medical centers in the U.S. to collaborate with their Indian colleagues. The company deploys next generation sequencing and other technologies in clinical applications and uses digital pathology for enabling concurrent global review of test results. The company also provides patients with peace of mind by delivering second opinions on all cases by at least two specialists from a global panel of pathologists.
Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit http://www.paradigmdx.com or visit us on Twitter @Paradigm_DX
About CORE DIAGNOSTICS
CORE Diagnostics is a clinical laboratory focused on next generation diagnostics for disease stratification and therapy selection. The company focuses on bringing the most advanced testing techniques and expertise to India and is the destination for all of India’s high-end diagnostic needs.
CORE Diagnostics is truly one of a kind, because of:
The company’s initial test offerings are in the areas of cardiology, oncology, reproductive disorders, endocrinology, and infectious diseases. For more information, please visit www.corediagnostics.in.